Anti-TGFBR3L monoclonal antibody
Pre-made anti-TGFBR3L monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to TGFBR3L/TGFBR3L products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP1911-Ab-1/ GM-Tg-hg-IP1911-Ab-2 | Anti-Human TGFBR3L monoclonal antibody | Human |
GM-Tg-rg-IP1911-Ab-1/ GM-Tg-rg-IP1911-Ab-2 | Anti-Rat TGFBR3L monoclonal antibody | Rat |
GM-Tg-mg-IP1911-Ab-1/ GM-Tg-mg-IP1911-Ab-2 | Anti-Mouse TGFBR3L monoclonal antibody | Mouse |
GM-Tg-cynog-IP1911-Ab-1/ GM-Tg-cynog-IP1911-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TGFBR3L monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP1911-Ab-1/ GM-Tg-felg-IP1911-Ab-2 | Anti-Feline TGFBR3L monoclonal antibody | Feline |
GM-Tg-cang-IP1911-Ab-1/ GM-Tg-cang-IP1911-Ab-2 | Anti-Canine TGFBR3L monoclonal antibody | Canine |
GM-Tg-bovg-IP1911-Ab-1/ GM-Tg-bovg-IP1911-Ab-2 | Anti-Bovine TGFBR3L monoclonal antibody | Bovine |
GM-Tg-equg-IP1911-Ab-1/ GM-Tg-equg-IP1911-Ab-2 | Anti-Equine TGFBR3L monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP1911-Ab-1/ GM-Tg-hg-IP1911-Ab-2; GM-Tg-rg-IP1911-Ab-1/ GM-Tg-rg-IP1911-Ab-2; GM-Tg-mg-IP1911-Ab-1/ GM-Tg-mg-IP1911-Ab-2; GM-Tg-cynog-IP1911-Ab-1/ GM-Tg-cynog-IP1911-Ab-2; GM-Tg-felg-IP1911-Ab-1/ GM-Tg-felg-IP1911-Ab-2; GM-Tg-cang-IP1911-Ab-1/ GM-Tg-cang-IP1911-Ab-2; GM-Tg-bovg-IP1911-Ab-1/ GM-Tg-bovg-IP1911-Ab-2; GM-Tg-equg-IP1911-Ab-1/ GM-Tg-equg-IP1911-Ab-2 |
Products Name | Anti-TGFBR3L monoclonal antibody |
Format | mab |
Target Name | TGFBR3L |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-TGFBR3L monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP1911-Ag-1 | Recombinant multi-species TGR3L/ TGFBR3L/ TGFR-3L protein |
Target information
Target ID | GM-IP1911 |
Target Name | TGFBR3L |
Gene ID | 100507588,100044509,688681,100428514,111091385,101100448,787301,111774203 |
Gene Symbol and Synonyms | GEMP,Gm14378,TGFBR3L,TGFR-3L |
Uniprot Accession | H3BV60 |
Uniprot Entry Name | TGR3L_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000260001 |
Target Classification | N/A |
The target: TGFBR3L, gene name: TGFBR3L, also named as TGFR-3L. Predicted to enable glycosaminoglycan binding activity; transforming growth factor beta-activated receptor activity; and type II transforming growth factor beta receptor binding activity. Predicted to contribute to transforming growth factor beta binding activity. Predicted to be involved in several processes, including blood vessel morphogenesis; regulation of transforming growth factor beta receptor signaling pathway; and transforming growth factor beta receptor signaling pathway. Predicted to be integral component of membrane. Predicted to be active in cell surface and extracellular space. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.